193 related articles for article (PubMed ID: 25232030)
1. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
Menezes DL; Holt J; Tang Y; Feng J; Barsanti P; Pan Y; Ghoddusi M; Zhang W; Thomas G; Holash J; Lees E; Taricani L
Mol Cancer Res; 2015 Jan; 13(1):120-9. PubMed ID: 25232030
[TBL] [Abstract][Full Text] [Related]
2. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
Lloyd RL; Urban V; Muñoz-Martínez F; Ayestaran I; Thomas JC; de Renty C; O'Connor MJ; Forment JV; Galanty Y; Jackson SP
Nucleic Acids Res; 2021 Sep; 49(15):8665-8683. PubMed ID: 34329458
[TBL] [Abstract][Full Text] [Related]
3. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
4. ATM and ATR as therapeutic targets in cancer.
Weber AM; Ryan AJ
Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
[TBL] [Abstract][Full Text] [Related]
5. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
[TBL] [Abstract][Full Text] [Related]
6. ATM and ATR Expression Potentiates HBV Replication and Contributes to Reactivation of HBV Infection upon DNA Damage.
Kostyusheva A; Brezgin S; Bayurova E; Gordeychuk I; Isaguliants M; Goptar I; Urusov F; Nikiforova A; Volchkova E; Kostyushev D; Chulanov V
Viruses; 2019 Oct; 11(11):. PubMed ID: 31683589
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
Weber AM; Drobnitzky N; Devery AM; Bokobza SM; Adams RA; Maughan TS; Ryan AJ
Oncotarget; 2016 Sep; 7(38):60807-60822. PubMed ID: 27602502
[TBL] [Abstract][Full Text] [Related]
8. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
Sultana R; Abdel-Fatah T; Perry C; Moseley P; Albarakti N; Mohan V; Seedhouse C; Chan S; Madhusudan S
PLoS One; 2013; 8(2):e57098. PubMed ID: 23451157
[TBL] [Abstract][Full Text] [Related]
9. RASSF1A promotes ATM signaling and
Gao A; Bai P; Zhang M; Yao Y; Herman JG; Guo M
Epigenomics; 2023 Nov; 15(22):1205-1220. PubMed ID: 38093706
[No Abstract] [Full Text] [Related]
10. ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.
Rondeau S; Vacher S; De Koning L; Briaux A; Schnitzler A; Chemlali W; Callens C; Lidereau R; Bièche I
Br J Cancer; 2015 Mar; 112(6):1059-66. PubMed ID: 25742469
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
Wang C; Wang G; Feng X; Shepherd P; Zhang J; Tang M; Chen Z; Srivastava M; McLaughlin ME; Navone NM; Hart GT; Chen J
Oncogene; 2019 Apr; 38(14):2451-2463. PubMed ID: 30532030
[TBL] [Abstract][Full Text] [Related]
12. Expression variations of DNA damage response genes ATM and ATR in blood cancer patients.
Parvez A; Mahjabeen I; Mehmood A; Khan AU; Nisar A; Kayani MA
Mol Genet Genomics; 2023 Sep; 298(5):1173-1183. PubMed ID: 37338595
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide induces ataxia telangiectasia mutated (ATM) protein-dependent γH2AX protein formation in pancreatic β cells.
Oleson BJ; Broniowska KA; Schreiber KH; Tarakanova VL; Corbett JA
J Biol Chem; 2014 Apr; 289(16):11454-11464. PubMed ID: 24610783
[TBL] [Abstract][Full Text] [Related]
14. ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors.
Ueno S; Sudo T; Hirasawa A
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008949
[TBL] [Abstract][Full Text] [Related]
15. ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition ≠ deletion.
Menolfi D; Zha S
Cell Biosci; 2020; 10():8. PubMed ID: 32015826
[TBL] [Abstract][Full Text] [Related]
16. A consensus set of genetic vulnerabilities to ATR inhibition.
Hustedt N; Álvarez-Quilón A; McEwan A; Yuan JY; Cho T; Koob L; Hart T; Durocher D
Open Biol; 2019 Sep; 9(9):190156. PubMed ID: 31506018
[TBL] [Abstract][Full Text] [Related]
17. ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies.
Botrugno OA; Bianchessi S; Zambroni D; Frenquelli M; Belloni D; Bongiovanni L; Girlanda S; Di Terlizzi S; Ferrarini M; Ferrero E; Ponzoni M; Marcatti M; Tonon G
Haematologica; 2020 Oct; 105(10):2440-2447. PubMed ID: 33054085
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.
Alfayomy AM; Ashry R; Kansy AG; Sarnow AC; Erdmann F; Schmidt M; Krämer OH; Sippl W
Eur J Med Chem; 2024 Mar; 267():116167. PubMed ID: 38308949
[TBL] [Abstract][Full Text] [Related]
19. The development of ataxia telangiectasia mutated kinase inhibitors.
Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
Mini Rev Med Chem; 2014 Oct; ():. PubMed ID: 25307308
[TBL] [Abstract][Full Text] [Related]
20. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
